Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$12.82
+7.2%
$9.93
$8.02
$18.80
$6.36B1.494.98 million shs7.58 million shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$18.35
+5.3%
$17.72
$13.45
$44.42
$1.61B0.26987,873 shs1.38 million shs
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$32.38
+1.9%
$34.00
$29.27
$60.87
$5.95B0.21.25 million shs1.74 million shs
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$34.99
+4.0%
$38.90
$15.16
$46.48
$5.34B2.213.01 million shs2.84 million shs
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+6.62%+33.04%+48.33%+12.22%-24.61%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
+5.64%-10.36%+9.55%-14.17%-55.43%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
+2.53%-3.05%+1.19%-6.50%-25.12%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
+4.01%-7.14%-4.69%+12.47%+110.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.9337 of 5 stars
3.22.00.00.32.13.30.0
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
3.5996 of 5 stars
3.51.00.04.42.71.70.0
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.6478 of 5 stars
3.53.00.00.03.01.70.6
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
3.8657 of 5 stars
2.43.00.03.52.51.71.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.43
Hold$15.0017.04% Upside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.93
Moderate Buy$54.27195.76% Upside
Legend Biotech Co. stock logo
LEGN
Legend Biotech
2.92
Moderate Buy$78.82143.42% Upside
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
2.80
Moderate Buy$40.8016.60% Upside

Current Analyst Ratings Breakdown

Latest IDYA, ELAN, LEGN, and TGTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$13.00 ➝ $15.00
4/22/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$84.00 ➝ $84.00
4/16/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
4/14/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $13.00
4/8/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
3/17/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$82.00 ➝ $80.00
3/12/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
3/12/2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$73.00 ➝ $75.00
3/6/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $12.00
3/4/2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
2/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $17.00
(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.43B1.44$2.65 per share4.84$12.63 per share1.01
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$7M229.58N/AN/A$12.10 per share1.52
Legend Biotech Co. stock logo
LEGN
Legend Biotech
$627.24M9.48N/AN/A$6.88 per share4.71
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$386.39M14.38$0.10 per share353.90$1.06 per share33.01
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$1.23B$0.7432.0414.402.504.60%6.78%3.03%N/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$274.48M-$3.59N/AN/AN/AN/A-26.74%-25.54%N/A
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$518.25M-$0.48N/AN/AN/A-66.92%-29.69%-19.45%5/13/2025 (Estimated)
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$12.67M$0.24N/A34.99N/A-5.42%-8.32%-3.40%N/A

Latest IDYA, ELAN, LEGN, and TGTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.34-$0.07+$0.27-$0.27$190.83 millionN/A
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/7/2025Q1 2025
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.19$0.03-$0.16$0.03$117.07 million$120.86 million
5/6/2025Q1 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A
3/11/2025Q4 2024
Legend Biotech Co. stock logo
LEGN
Legend Biotech
-$0.39$0.07+$0.46$0.07$179.00 million$186.50 million
3/3/2025Q4 2024
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
$0.08$0.15+$0.07$0.15$100.67 million$108.19 million
2/25/2025Q4 2024
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.15$0.14-$0.01-$0.02$1.01 billion$1.02 billion
2/13/2025Q4 2024
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.67-$1.49-$0.82-$1.49$7.00 million$7.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Legend Biotech Co. stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.66
2.55
1.31
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
14.97
22.93
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.27
4.98
4.90
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
1.27
4.59
3.91

Institutional Ownership

CompanyInstitutional Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
70.89%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
58.58%

Insider Ownership

CompanyInsider Ownership
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.89%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
3.50%
Legend Biotech Co. stock logo
LEGN
Legend Biotech
0.02%
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
10.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,800496.46 million491.54 millionOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.58 million84.47 millionOptionable
Legend Biotech Co. stock logo
LEGN
Legend Biotech
1,070183.65 million182.60 millionOptionable
TG Therapeutics, Inc. stock logo
TGTX
TG Therapeutics
290158.78 million139.32 millionOptionable

Recent News About These Companies

Q3 Earnings Estimate for TG Therapeutics Issued By B. Riley
J.P. Morgan Remains a Buy on TG Therapeutics (TGTX)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$12.82 +0.86 (+7.16%)
Closing price 05/12/2025 03:59 PM Eastern
Extended Trading
$12.78 -0.03 (-0.24%)
As of 08:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$18.35 +0.93 (+5.34%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$18.35 0.00 (0.00%)
As of 07:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$32.38 +0.60 (+1.89%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$31.80 -0.58 (-1.79%)
As of 08:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

TG Therapeutics stock logo

TG Therapeutics NASDAQ:TGTX

$34.99 +1.35 (+4.01%)
Closing price 05/12/2025 04:00 PM Eastern
Extended Trading
$34.88 -0.11 (-0.30%)
As of 08:11 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.